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Abstract 
Background: Camelids possess unique functional heavy chain antibodies, which can be produced and modified 
in vitro as a single domain antibody (sdAb or nanobody) with full antigen binding ability. Production of sdAb in con‑
ventional manner requires active immunization of Camelidae animal, which is laborious, time consuming, costly and 
in many cases not feasible (e.g. in case of highly toxic or infectious antigens).
Results: In this study, we describe an alternative pipeline that includes in vitro stimulation of naïve alpaca B‑lympho‑
cytes by antigen of interest (in this case endothelial cell binding domain of OspA of Borrelia) in the presence of recom‑
binant alpaca interleukins 2 and 4, construction of sdAb phage library, selection of antigen specific sdAb expressed on 
phages (biopanning) and confirmation of binding ability of sdAb to the antigen. By joining the in vitro immunization 
and the phage display ten unique phage clones carrying sdAb were selected. Out of ten, seven sdAb showed strong 
antigen binding ability in phage ELISA. Furthermore, two soluble forms of sdAb were produced and their differential 
antigen binding affinity was measured with bio‑layer interferometry.
Conclusion: A proposed pipeline has potential to reduce the cost substantially required for maintenance of camelid 
herd for active immunization. Furthermore, in vitro immunization can be achieved within a week to enrich mRNA cop‑
ies encoding antigen‑specific sdAbs in B cell. This rapid and cost effective pipeline can help researchers to develop 
efficiently sdAb for diagnostic and therapeutic purposes.
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Background
Family Camelidae is in the spotlight in antibody engi-
neering. Serum of camelids contain both conventional 
heterotetrameric antibodies and unique functional heavy 
(H)-chain antibodies (HcAbs), which were discovered 
in early 90 s [1]. This type of antibodies can form up to 
75% of whole antibody repertoire [1]. Lack of CH1 in 
the H chain causes failure to pair with a light chain that 
results in the lower molecular weight (approx. 90  kDa) 
in comparison to conventional antibodies (approx. 
150 kDa). VH regions of HcAbs, called VHH, are highly 
homologous with VH regions of conventional antibodies. 
However, mutational hotspots within VHH have been 
identified. Such hotspots are necessary for its stabiliza-
tion, avoiding pairing with light chains and conferring 
high refolding ability [2]. The VHH regions can be ampli-
fied with PCR from HcAbs sequence to produce smaller 
antibody fragments (e.g. 15 kDa) with full binding ability. 
These small fragments are called nanobodies® (Nbs) or 
single-domain antibodies (sdAb) [3].
sdAb consist only of VHH regions and are able to 
penetrate into difficult areas due to their small size or 
get through physical tissue that both HcAbs and con-
ventional antibodies are not able to access [3]. sdAb can 
recognize unique epitopes, such as concave epitopes and 
thus have the possibility of succeeding in therapies where 
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conventional antibodies commonly fail [4–8]. Moreo-
ver, sdAb have been successfully used also for diagnosis 
and inhibition of several types of cancer [9–12]. A huge 
advantage of using sdAb as therapeutics is the possibility 
of oral administration. By contrast, conventional antibod-
ies have to be intravenously or subcutaneously injected. 
Harmsen et al. [13] successfully used sdAb orally to treat 
diarrhea in piglets. Beside medical applications, sdAbs 
are also used in research as tools for affinity chromatog-
raphy [14], chromatin immunoprecipitations [15] or as 
crystallization chaperones in x-ray crystallography [16].
A conventional pipeline for nanobody synthesis 
includes active immunization of healthy Camelidae ani-
mals, extraction of mRNA from blood of immunized 
animals and ligation of VHH specific cDNA in phagemid 
followed by selection of antigen specific antibody by 
phage display [17]. Recently, a ribosome display was also 
employed for sdAb production as an alternative to phage 
display [18, 19]. A conventional pipeline has several dis-
advantages such as high cost for maintaining Camelidae 
animals and the comparatively longer period necessary 
for immunization. Furthermore, when production of 
sdAb towards multiple target antigens is desired, it would 
be necessary to maintain a large number of camelids.
Antigen-induced in vitro production of antibodies was 
suggested as an alternative method to generate conven-
tional antibodies [20–22]. However, this alternative has 
never been used in the sdAb production pipeline. This 
method is based on the theory of spontaneous recombi-
nation of V-, D-, J- segments of antibodies in healthy B 
lymphocytes [23]. The co-cultivation of isolated B cells 
with target antigens triggers up-regulation of natural spe-
cific antibodies in an antigen-dependent manner [20]. It 
is important to note that, during the process of in vitro 
immunization interleukins (ILs, mainly IL-2 and IL-4) 
from the family Camelidae are essential for B cells activa-
tion and differentiation.
In the present study we describe a rapid pipeline for 
sdAb production that could replace the conventional 
technique which relies on the animal immunization. The 
antigen used in this study is an endothelial cell binding 
domain of OspA (outer surface protein A) of neuroin-
vasive Borrelia. This domain is also called as HUVEC 
(human umbilical vein endothelial cells) binding domain 
(thus hereafter designated as H-OspA). This protein is 
responsible for binding and translocation of Borrelia 
through the blood–brain barrier (BBB) [24, 25]. In the 
experimental pipeline, we immunized B cells in  vitro 
with H-OspA, mRNA was isolated, reverse transcribed, 
gene fragment encoding VHH region was amplified and 
used to construct sdAb phage library. The library was 
screened to isolate antigen binding VHH fragment and 
antigen specific phage clones were sequenced. Based on 
sequence alignment, clones were grouped into ten fami-
lies and representative of each family was tested for their 
binding affinity to antigen with dot-blotting, and phage 
ELISA. Furthermore, the clones with highest and lowest 
affinity were produced as soluble sdAb and their affinities 
were measured by bio-layer interferometry. The pipeline 
described here allows rapid and low-cost production of 
antigen specific sdAbs with minimal use of animals.
Methods
Synthesis of IL‑2 and IL‑4
Interleukins IL-2 and IL-4 of alpaca, necessary for 
in  vitro immunization, were produced. In short, IL-2 
and IL-4 coding sequences were retrieved from the Gen-
Bank (KM205215.1 and KM205216.1, http://www.ncbi.
nlm.nih.gov/) and synthesized commercially (Invitrogen, 
Slovakia) with flanking sequences containing restriction 
sites for BamHI at 5′ and amber stop codon followed by 
SalI at 3′ end. DNA fragments were digested with BamHI 
and SalI (Thermo Fisher Scientific, Slovakia) and ligated 
into pQE-30-mCherry-GFP plasmid (Fig.  1, in-house 
modified vector pQE-30 UA, Qiagen). Please note that 
in this vector mCherry serves as stuffer sequence, which 
is cut out during the digestion of vector with restriction 
enzymes, whereas incorporation of amber stop codon at 
3′ of IL gene ensures no fusion of GFP to ILs. Ligation 
mix was purified using NucleoSpin (Macherey–Nagel, 
Germany) and transformed into E. coli SG13009 for IL-2, 
and M15 strain for IL-4 (Qiagen, Germany). Transfor-
mants were selected from LB agar plates (lysogeny broth 
agar, 10 g/L tryptose, 10 g/L NaCl, 10 g/L yeast extract, 
2% bacteriological agar) supplemented with 1% glucose 
(G), 5  µg/mL Kanamycin (K) and 5  µg/mL Carbenicil-
lin (C). Presence of IL-2 or IL-4 encoding gene in trans-
formants was confirmed by sequencing (vector specific 
primers UA Insertom F and R, presented in Table 1).
Purification of interleukins
Clones were cultivated in Terrific broth (15  g/L tryp-
tose, 30 g/L yeast extract, 12.5 g/L NaCl, 2.5 g/L MgCl2/
MgSO4, 100 µl/L metal mix, 7.5 mL/L glycerol) supple-
mented with 1% glucose, 5 µg/mL Carbenicillin and 5 µg/
mL Kanamycin (TB/G/K/C) until OD600  =  6. Bacterial 
cells were pelleted (centrifugation at 6000 × g for 10 min) 
and resuspended in fresh TB medium without glucose 
(TB/K/C). Protein expression was induced with 1  mM 
IPTG (Fermentas, Slovakia) for 8 h at 20 °C. After induc-
tion, cells were pelleted (17,880 × g for 10 min) and lysed 
in lysis buffer (0.03  M Na2HPO4, 0.5  M NaCl, 0.001% 
Tween 20, 10% glycerol) with four freeze–thaw cycles fol-
lowed by sonication (2 cycles; 30-s pulses, 100% ampli-
tude). His tagged- ILs were purified with nickel affinity 
chromatography (Ni–NTA agarose beads, ABT, Spain) 
Page 3 of 13Comor et al. Microb Cell Fact  (2017) 16:13 
as per manufacturer´s instructions. Eluted fraction was 
evaluated by SDS-PAGE and Western blotting using anti-
His probe 1:3500 (Thermo Fisher Scientific). Molecular 
mass of purified proteins was identified on MALDI–TOF 
MS as described by Mlynarcik et  al. [24]. Aliquots of 
purified ILs were stored at −20 °C either in PBS or in PBS 
containing 20% glycerol until use.
Assessment of toxicity of interleukins and cell proliferation
Peripheral blood mononuclear cells (PBMCs) were 
cultured as described previously [25, 26]. Cells were 
incubated for 24 h (37 °C, 95% humidity, and 5% CO2) in 
the presence of 1 ng/µL of each IL, with or without 20% 
glycerol. This concentration of ILs was used previously 
for in vitro immunization of human B cells [26]. Cell cul-
tures without ILs were run alongside as negative controls. 
Cell viability/proliferation was assessed with XTT pro-
liferation test according to manufacturer’s instructions 
(Panreac Applichem, Germany). In brief, 100  µl of each 
cell suspension was transferred to 96-well plate and 50 µl 
of XTT solution was added. Cells were incubated for 2 h 





Fig. 1 Vector map of pQE‑30‑mCherry‑GFP plasmid (4880 bp). PT5 T5 promoter, lac O lac operator, RBS ribosome binding site, ATG Start codon, 
6xHis His tag sequence, MCS I/MCS II multiple cloning sites; mCherry—red fluorescent protein that serve as stuffer, GFP, green flourescent protein; 
Stop codon; Col E1, Col E1 origin of replication; Ampicillin, ampicillin resistance gene. Note that incorporation of the stop codon at 3′ of insert 
produces recombinant protein without GFP fusion
Table 1 Sequences of primers used in the PCR
Primer Sequence 5′–3′ Method
sDAb‑Not‑R CCAGCGGCCGCTSWGGAGACRGTGACCWGGGTCC Reverse transcription of RNA; VHH amplification
sDAb‑NcoAsc‑F CGGCCATGGCCGGGCGCGCCGCCSAGGTGSAGSTSSWGSMGTC VHH amplification
pSex Insertom F ATGAAATACCTATTGCCTACGGCAG Control PCR for electroporation
pSex Insertom R CTACAACGCCTGTAGCATTCCAC Control PCR for electroporation
UA Insertom F1 CGCATCACCATCACCATCACG Control PCR for electroporation, plasmid pQE‑30‑
mCherry‑UA‑GFP
UA Insertom R1 ACCAAATTGGGACAACACCAGTG Control PCR for electroporation, plasmid pQE‑30‑
mCherry‑UA‑GFP
sDAb‑BamHI‑F AATGGATCCSAGGTGSAGSTSSWGSMGTC VHH amplification for production of soluble sdAb
sDAb‑SalI‑R GCTGTCGACCTATSWGGAAGACRGTGACCWGGGTCC VHH amplification for production of soluble sdAb
H‑OspA F AGGATATCTAACGAAAAGGGTGAAACA For production of H‑OspA
H‑OspA R without Stop ATAGTCGACTTCTATGTCAGAGTCATCAAGTGC For production of H‑OspA with GFP fusion
H‑OspA R with Stop ATAGTCGACTCATTCTATGTCAGAGTCATCAAGTGC For production of H‑OspA without GFP fusion
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FC Filter-Based Microplate Photometer (Thermo Fisher 
Scientific) at 475 nm with reference absorbance at wave-
length 660 nm. The proliferation (d) was measured as fol-
lows d = (a − b) − c; where in a—absorbance at 475 nm, 
b—absorbance at 660  nm and c—absorbance of blank 
medium (reference absorbance at 660 nm was also sub-
tracted for c). Measurements were performed in quadru-
plicate. The assay was repeated three times.
Production of H‑OspA
Briefly, sequence encoding H-OspA was amplified by 
PCR from genomic DNA of SKT–7.1 strain of Borrelia 
bavariensis using primers depicted in Table  1. Purified 
PCR products were digested with restriction enzymes 
EcoRV and SalI (Thermo Scientific), ligated into pre-
viously digested pQE-30-mCherry-GFP plasmid. To 
produce his-tagged H-OspA without GFP fusion we 
incorporated stop codon in antisense primer (Table  1, 
primer: H-OspA R with Stop), whereas, for the produc-
tion of his-tagged OspA with C-terminal GFP fusion 
antisense primer was without stop codon (Table  1, 
primer: H-OspA R without Stop). Transformants were 
selected from LB agar plates supplemented with 1% glu-
cose (G), 5 µg/mL Kanamycin (K) and 5 µg/mL Carbeni-
cillin (C). Proteins were overexpressed with 1 mM IPTG 
for 16 h at 20  °C. Purification of proteins in native state 
was performed as described above.
In vitro immunization of B cells
100 mL of heparinized blood was collected from 4 years 
old healthy alpaca. PBMCs were immediately isolated 
by density centrifugation using Histopaque medium 
(Sigma-Aldrich, Germany) according to manufacturer´s 
instructions. PBMCs in the buffy coat were trans-
ferred into a new tube and washed with eRDF medium 
(RPMI:DMEM:F12 in the ratio of 2:1:1 as described in 
[27]). PBMCs were pelleted (400×g, 20 min) and resus-
pended in 5  mL of 20  mM Leu–Leu methyl-ester hyd-
robromide prepared in eRDF (LLME) (Sigma-Aldrich). 
Cells were incubated for 20  min at room temperature 
and harvested by centrifugation (400×g, 20  min). Cell 
pellet was washed with eRDF medium and again resus-
pended in 1 mL of eRDF. Cell density was measured by 
BD Accuri C6 flow cytometer (BD Biosciences, USA) and 
adjusted to 1  ×  106 cells/mL using eRDF. Cell suspen-
sions (2  mL/well) were incubated overnight in 12-well 
plates (37  °C, 95% humidity, 5% CO2) with 1  ng/mL of 
each IL, 0.25  µM Class A CpG oligonucleotide ODN 
2216 (InVivoGen, USA) and 20 µL/mL Mycokill (PAA 
Laboratories, Germany). After incubation, antibody pro-
duction was induced by adding 10  µg/mL of his tagged 
H-OspA (antigen). Cells were incubated for 24 h before 
adding 0.25 µM Class B CpG oligonucleotide ODN 2006 
(InVivoGen, strong activator of B lymphocytes with 
weak stimulation of IFN-α secretion) to each well, and 
the incubation was continued until 72  h. Cell viability 
was checked every day under the microscope and cells 
count (proliferation) was performed by flow cytometry 
(BD Accuri C6 flow cytometer) using 2 µl of cell culture 
resuspended in 20 ml of fresh eRDF. After 72 h incuba-
tion, total RNA was isolated from the cells using PureZol 
(Bio-Rad, USA) and treated with DNaseI (Thermo Fisher 
Scientific) according to manufacturer’s instructions.
VHH amplification
cDNA was reverse transcribed from RNA using Rever-
tAid reverse transcriptase (Thermo Fisher Scientific) 
and sDAb-Not-R primer (Table  1) according to manu-
facturer’s instructions. VHH were PCR amplified using 
gene-specific primers that amplifies sequence between 
Framework 1–4 (sDAb-NcoAsc-F and sDAb-Not-R; 
Table 1). Amplicons were purified by NucleoSpin (Mach-
erey–Nagel, Germany) and digested with restriction 
enzymes NcoI and NotI (Thermo Fisher Scientific) for 
1 h at 37 °C as per manufacturer´s instructions. Digested 
DNA fragments were column purified and ligated into 
the phagemid pSex81 (Fig.  2, Progen, Germany) and 
transformed into E. coli XL-1 blue (New England Bio-
labs, Germany). This ligation allows fusion of VHH with 
pIII protein of the phage. Transformants were selected 
randomly from LB agar plates (containing 5  µg/mL of 
Carbenicillin) and subjected for the sequencing using 
vector specific primers pSex Insertom F and R (Table 1) 
on ABI 3100 Avant sequencer (3.1 big-dye terminator kit, 
thermo scientific) to analyze the diversity of the library. 
The diversity was determined by distance matrix created 
in Geneious pro R9 (Biomatters LtD. New Zealand). All 
E. coli colonies were scraped in 10 mL of 50% glycerol in 
LB medium and stored at −20 °C for further experiments 
(this suspension of E. coli is referred to as a library, which 
contains large repertoire of VHH variants cloned into 
pSex81 backbone).
Phage display
Phage display was conducted as described before [28]. 
In brief, 100 µL of the library was grown in 2  ×  TY 
medium (16  g/L tryptose, 10  g/L yeast extract, 5  g/L 
NaCl, pH 7) supplemented with 5  µg/mL Tetracycline 
and 1% glucose up to OD600  =  0.5. Cells were super-
infected with helper phage M13K07 (20 phages/cell, 
Progen Biotechnik, Germany) for 1 h at 37  °C (30 min 
without shaking followed by 30  min with shaking at 
250 rpm). Superinfected cells were incubated overnight 
in 2 × TY medium supplemented with 5 µg/mL Tetra-
cycline, 5 µg/mL Carbenicillin and 5 µg/mL Kanamycin 
to allow phage escaping. Phages were precipitated with 
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polyethylenglycol (20% PEG, 2.5  M NaCl). Number of 
phages were calculated by titration as described by Thie 
[28] on agar plates containing 2  ×  TY medium sup-
plemented with 1% glucose, 5 µg/mL Tetracycline, and 
5  µg/mL Carbenicillin. The selection (biopanning) of 
phages expressing antigen specific sdAb on pIII protein 
was performed by affinity chromatography. In short, 
precipitated phages were resuspended in phage dilution 
buffer (10 mM TrisHCl, 20 mM NaCl, 2 mM EDTA) and 
2 ×  1011 of phage particles were incubated with metal 
affinity (Co++) magnetic beads (Bruker, Germany) for 
1  h at room temperature. Beads were spun and super-
natant was recovered. This step removes the phages that 
bind nonspecifically to magnetic beads. The superna-
tant containing phages was then incubated with anti-
gen immobilized on the metal affinity (Co++) magnetic 
beads at 4 °C overnight with constant shaking. Magnetic 
beads were washed 10 times as follows: first washing 
with PBS supplemented with 0.1% Tween20 (PBS-T) for 
overnight at 4 °C followed by eight washings with PBS-T 
(each for 2 min at 4 °C), and the last washing with PBS 
for 2  min at 4  °C). Before each washing beads were 
transferred to new tube to avoid carryover of the phages 
that possess affinity to the plastic. Antigen specific sdAb 
were eluted by PBS containing 10  µg/mL trypsin (pH 
7.4, Promega, USA). Number of eluted phage particles 
were calculated by titration as described above. Three 
rounds of biopanning were performed and clones from 
last titration plate were used for amplification of phage 
clones.
Amplification of phage clones
Twenty clones were picked randomly from the LB plates 
used in the last titration, sequenced with vector specific 
primers (pSex Insertom F and R, Table  1) as described 
above. VHH sequences were aligned (Geneious pro 9.0) 
and grouped based on sequence similarity. Representa-
tive E. coli clone from each group were amplified and 
phages were escaped by superinfection and precipitated 
as described before. Protein concentration of the phage 
pellet was measured by Bradford method and the con-
centration was set to approximately 50 ng/µl with phage 
dilution buffer. Phages were stored at −80 °C until their 
use in phage dot blotting.
Fig. 2 Vector map of pSex81 plasmid (4864 bp). RBS, ribosome binding site; Signal peptide—pel‑B leader sequence; Vh V and VI V regions, scFv 
single‑chain fragment variable that serves as stuffer which is replaced by VHH sequence encoding sdAb; gene 3, gene for pIII surface protein. Note 
that sdAb are fused to pIII. T7 terminator; Bla gene, β‑lactamase gene which gives ampicillin resistance; Col E1, Col E1 origin of replication
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Qualitative phage dot blotting
Phage dot blot was performed to assess affinity of sdAb 
clones to H-OspA (antigen). In short, PVDF mem-
brane (Millipore, USA) was first pre-wetted in methanol 
and then in PBS, and 2 µL of each diluted phage clone 
expressing sdAb was spotted in duplicate on two sepa-
rate membranes (one membrane was used as input con-
trol to confirm presence of phages on membrane—phage 
input control, and second membrane was used for phage 
dot blot). Membranes were blocked in Odyssey blocking 
buffer (LI-Cor, USA) for 1 h at room temperature. Mem-
brane for phage input control was incubated with anti-
pVIII antibody (1:1000 GE Healthcare, United Kingdom), 
washed two times with PBS-T and the interaction was 
detected by IRDye detection reagent (LI-Cor, USA). The 
second membrane with phages (kept for phage dot blot) 
was incubated with GFP tagged H-OspA for 1 h at room 
temperature. After three washings with PBS-T, the inter-
action was detected by anti-GFP antibody conjugated 
with C770 IRdye (1:20,000 Biotium, USA). Signals were 
captured on LI-Cor Odyssey CLx (LI-Cor, USA). The 
experiment was repeated three times.
Another control was kept in the experiment to show 
that anti-pVIII antibody used in this experiment detects 
phage coat. For this helper phage MK13K07 (which 
has no VHH sequence) was spotted on the membrane, 
blocked in Odyssey blocking buffer and then incubated 
with anti-pVIII antibody. After washings with PBS-T 
interaction was detected by IRDye detection reagent.
To confirm that neither GFP tagged H-OspA, nor 
anti GFP antibody bind non-specifically to helper phage 
coat proteins, MK13K07 was spotted on the membrane 
and the membrane was included in phage dot blotting 
described above.
For an antigen input control, GFP tagged H-OspA 
binding domain was spotted on the separate membrane 
and presence of tagged protein was detected by anti-
GFP antibody conjugated with C770 IR dye (1:20,000, 1 h 
incubation at room temperature, Biotium, USA).
Quantitative phage ELISA
Phage ELISA was performed to measure affinity of selected 
sdAb clones to H-OspA. In brief, 96-well plate (Nunc, 
Denmark) was coated with 100 μL his-tagged H-OspA 
(no GFP tag) and a non-related protein (his-tagged serum 
amyloid A of Salmo salar fused with GFP; SAA; previ-
ously produced in our lab [2]) in carbonate/bicarbonate 
buffer (15  mM Na2CO3, 35  mM NaHCO3, pH =  9.6) at 
concentration of 50 μg/mL at 4  °C overnight. Wells were 
blocked by PBS-T for 1 h with gentle agitation. The plate 
was subsequently washed three times with PBS-T and 
100 μL of phage clones (approx. 100  ng, diluted in PBS-
T) were added to each well and incubated for 1 h at room 
temperature with gentle agitation. After three washings 
with PBS-T, 100 μL of anti-pVIII antibody (1:1000) was 
added to the wells, and the plate was incubated for 1 h at 
room temperature. After three washings, secondary anti-
Mouse antibody conjugated with HRP (GE Healthcare, 
1:1000) was added and the plate was incubated for 1 h at 
room temperature. The plate was washed three times and 
100 μL of ELISA-HRP substrate 680 (Li-Cor) was added, 
and the plate was incubated in dark for 15 min. Twenty-
five microliters of stop solution was added to each well and 
the plate was incubated for another 5 min in dark. Finally, 
the plate was read at 700 nm on Li-Cor Odyssey CLx. The 
assay was performed in triplicate.
To assess unspecific binding of phage clones to plastic, 
H-OspA and SAA proteins were excluded from above 
experiment. To rule out any non-specific binding of anti-
pVIII and anti-Mouse antibodies to H-OspA, three wells 
coated with H-OspA were directly incubated with pri-
mary and secondary antibodies.
Production of soluble sdAbs
DNA was extracted from E. coli clones infected with 
PhC11 and PhC12. The sequences encoding VHH were 
amplified by primers with BamHI overhang in sense 
and SalI in antisense (Table  1). Please note that anti-
sense primer contained stop codon downstream to SalI 
restriction site. Amplified DNA was digested, ligated 
into pQE-30-mCherry-GFP, and transformed into E. coli 
SG130009. The soluble sdAb were overexpressed in TB 
medium containing 1 mM IPTG (16 h at 20 °C), and puri-
fied under native conditions using nickel affinity chro-
matography (Ni–NTA agarose beads, ABT, Spain) as per 
manufacturer´s instructions. The presence of sdAbs and 
their purity was checked by SDS-PAGE.
Bio‑layer interferometry
Bio-layer interferometry was performed on BLItz sys-
tem (fortéBIO, USA) as per manufacturer’s guidelines. 
Streptavidin-coated Dip-and-Read Biosensors (fortéBIO) 
were equilibrated by assay buffer (PBS-T, 0.02% Tween-
20) for 60  s. H-OspA, freshly biotinylated by EZ-Link™ 
Sulfo-NHS-SS-Biotin (ThermoFisher Scientific) accord-
ing to manufacturer’s instructions, was subsequently 
bound to the sensor for 150 s at concentration of 250 μg/
mL. Free surface of biosensor was blocked by biocytin 
(Sigma-Aldrich, 10 μg/mL) for 90 s. The sensor was then 
washed with assay buffer for 60 s. The affinity of soluble 
sdAb was measured in three different concentrations 
(7.25, 14.5, and 29  μM) for 240  s (120  s for association 
step and 120 s for dissociation step). For blank measure-
ment, the biosensor was coated with H-OspA and asso-
ciation–dissociation steps were performed with assay 
buffer without sdAb. To evaluate the affinity constant KD 
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(equilibration between constants of association rate—Ka 
and dissociation rate—Kd) of the sdAb, blank measure-
ment was subtracted from the measurements of the 
sdAb, and global fitting (1:1) was used. Blitz Pro 1.1.0.31 
software (fortéBio) was used to measure KDs.
Results
Production of IL‑2 and IL‑4
Interleukins 2 and 4 of Vicugna pacos (alpaca) are not 
commercially available. Although ILs from other species 
(like sus scrofa) are available, their ability to proliferate/
activate cross species B cells is doubtful. Thus we decided 
to produce recombinant ILs of alpaca. Synthetic genes 
encoding IL-2 and IL-4 were ligated into the expression 
vector, transferred into E. coli strains and proteins were 
overexpressed with IPTG. Interleukins were purified in 
native state with nickel affinity chromatography. Approx-
imately 61 mg of IL-2 per liter of LB medium and 35 mg 
of IL-4 per liter were obtained. The purity of ILs was veri-
fied by SDS-PAGE and Western blot using anti-His probe 
(Fig.  3, panel A). The molecular weights of his-tagged 
ILs were confirmed on the MALDI–TOF, which were in 
accordance with the masses predicted in silico (17 kDA 
for IL-2 and 14 kDa for IL-4; Fig. 3, panel B).
Recombinant ILs showed cell proliferation and non‑toxicity
Assessment of cytotoxicity of purified ILs was necessary 
to assess prior to their use in in vitro immunization. Cell 
density was increased significantly in case of both ILs 
when used with (IL-2 d-0.037 and IL-4 d-0.047; negative 
control d-0.029) or without glycerol (IL-2 d-0.048 and 
IL-4 d-0.04; negative control d-0.029) (Fig. 4). By adding 
glycerol in this experiment we tested its toxic effect on 
the PBMCs in in vitro immunization. Non-toxicity of ILs 
resuspended in 20% glycerol was confirmed (Fig. 4).
sdAb phage clones isolated from the library constructed 
from in vitro immunized B cell
Peripheral blood monocytes were stimulated with 
H-OspA. Throughout in  vitro immunization cell viabil-
ity was evaluated everyday microscopically, wherein all 
cells were viable (data not shown). Similarly, there was 
no reduction in the cell count during and at the end of 
in  vitro immunization (e.g. in cells incubated with anti-
gen initial cell count was 1 × 106 cells/mL; cell count at 
the end of immunization was 5.2 × 106 cells/mL).
Total RNA isolated from antigen stimulated PBMCs 
was reverse transcribed and VHH fragments were 












































Fig. 3 Purity of ILs was assessed by SDS‑PAGE and Western blotting using anti‑His probe (a). Arrows in a indicates ILs. Molecular mass of the ILs was 
also confirmed by MALDI–TOF (b). Masses 17.026 kDa of IL‑2 and 14.332 kDa of IL‑4 exactly matched with their predicted molecular weights (in silico 
prediction in Geneious Pro software)
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phagemid and a library for expression of sdAb on pIII 
was generated in E. coli XL-1 blue. A total of 1.3 × 106 
transfectants were obtained. Clones were picked ran-
domly and sequenced with vector specific primers. 
Nucleotide sequences were translated in silico and amino 
acid sequences were used to plot distance matrix (Fig. 6). 
Number of non-identical residues (>28 residues) among 
the VHH sequences (Fig.  6) confirms the high diversity 
of the library. Hundred microliters of library was ampli-
fied in 2 × TY medium, phages were escaped with helper 
phage and the number of phages were calculated with 
phage titration, in which we obtained 2.04 × 1016 CFU/
mL. Escaped phages (2 × 1011) were incubated with the 
same antigen used in in  vitro immunization to capture 
the antigen binding phages (biopanning). Number of 
antigen binding phages in the eluate obtained from bio-
panning were calculated again with titration, wherein 
1  ×  104 CFU/mL (approx. 1  ×  104 phages/mL) were 
counted. Randomly picked clones from the last titra-
tion were sequenced, translated in silico and amino acid 
sequences were aligned. Alignment was used to group 
clones with similar sequences. In total ten groups, each 
representing distinct full length VHH sequence were 
made (Fig. 7). Representative E. coli clone of each group 
was subjected for phage escaping, and phage clones were 
then used in phage dot blotting.
Assessment of binding of sdAb to antigen
Qualitative phage dot blotting confirmed the binding 
ability of sdAb expressed on phages to the antigen used 
in in vitro immunization (Fig. 8). To check whether the 
antigen interacts with phage coat proteins, helper phage 
was incubated with the antigen and subsequently with 
secondary antibody. No signal was noticed in this case 
(Fig. 8, panel B), which overrides the possibility of cross 
reactivity between antigen and sdAb carrying phage 
particle.
Quantitative measurement of binding affinities
To assess strength of the binding between phages carry-
ing sdAb and antigen, quantitative phage ELISA was per-
formed (Fig. 9). The strongest affinity was found for clone 
PhC11 (RFU 21,586) followed by PhC1 (RFU 7830) and 
PhC3 (RFU 7210). Clones PhC5 (RFU 651; P =  0.5361, 
95%). PhC9 (RFU 993; P = 0.4657, 95%) and PhC19 (RFU 
496; P = 0.112, 95%) showed no significant binding affin-
ity to H-OspA, whereas PhC10 and PhC19 showed weak 
non-specific binding to the non-related antigen SAA. 
None of the Phage clone, except PhC19 (RFU  =  236), 
showed binding to plastic.
Two clones, PhC11 (RFU  =  21,586) and PhC12 
(RFU  =  1976), which showed statistically significant 
strongest and weakest binding to H-OspA respec-
tively were selected for measurement of KD by bio-layer 
interferometry. Soluble sdAb produced from PhC11 
and PhC12 (Fig.  10) showed KD of 4.291 ×  10E−6 and 
7.905 × 10E−4, respectively (Table 2).
Discussion
With current interest in the applications of sdAbs in 
therapeutics and diagnostics, it is now necessary to over-
come major hurdles in the isolation and synthesis of 
antigen-specific sdAb (e.g. time, cost, necessity of several 
camelid animals etc.). Thus, the primary aim of this study 





IL-2 IL-4 Negative control 










Fig. 4 PBMCs were cultured with (IL‑2 and IL‑4) or without interleu‑
kins (negative control) to assess any possible cytotoxicity of recom‑
binant ILs as well as to confirm their ability to induce lymphocyte 
proliferation (d). Proliferation assay was performed using XTT. ILs were 
used with (gray columns) or without glycerol (black columns) to rule 
out any inhibitory effect of glycerol. * statistically significant induction 
(P < 0.01, paired t test) in the lymphocyte proliferation when com‑









Fig. 5 a Arrow indicates VHH fragment amplified from in vitro 
immunized lymphocytes. b Arrow indicates amplicons from the PCR 
performed to confirm insertion of VHH in pSex81 vector. Amplifica‑
tion was perfomed with pSex Insertom F and R primers. Note that 
this PCR add 150 nt to insert as primers are complimentary to vector 
(thus the molecular weights are higher ~700 bp)













VHH-H3 VHH-H5 VHH-H6 VHH-H7 VHH-H8 VHH-H19 VHH-H10 VHH-H11 VHH-H12 VHH-H14 VHH-H4 KF013132
Fig. 6 Sequence distance matrix built on in silico translated sequences of randomly picked clones from E. coli sdAb library (clones were designated 
as VHH‑H3, 5, 7 etc.). KF013132—accession number of reference sequence from the Genbank. Number of amino acid residues not identical are 
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Fig. 7 Amino acid sequence alignment of randomly picked clones from last titration of biopanning. VHH‑H‑OspA‑1, 3, 5 etc.—representative 
amino acid sequence pertaining to each group (Clones with humongous sequences were clustered). CDR complementary consensus sequence. 
Dots—sequence homology. Dashes—gaps in the alignment. Amino acid letters appear in alignment in case of heterogeneity. Note the high level of 
heterogeneity in CDR3 followed by CDR2 and CDR1. Frameworks are relatively conserved




HP PhC1 PhC3 PhC5 PhC7 PhC9 PhC10 PhC11 PhC12 PhC15 PhC19
Fig. 8 Qualitative phage dot blot. HP—helper phage spotted on the membranes. PhC1, 3, 5 etc.—escaped phages were spotted on the mem‑
branes. a Membrane with spotted phages was incubated with anti‑pVIII antibody and then IRDye Detection antibody. b Membrane with phages 
was incubated with H‑OspA‑tagged with GFP and then anti‑GFP antibody conjugated with C770 IRdye. c Input control for the antigen—H‑OspA‑
tagged with GFP was spotted on the membrane and incubated with anti‑GFP antibody conjugated with C770 IRdye. All secondary antibodies were 
conjugated with infra‑red flurofores which enables quantification of signals in linear mode on infra red scanner (LI‑Cor). Figures in the parenthesis 
indicates relative fluorescence unit (RFU)
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production of sdAbs with antigen specific binding affin-
ity. Here, as an antigen we used endothelial cell binding 
domain of OspA responsible for adhesion of Borrelia to 
brain microvascular endothelial cells, that further leads 
to translocation of pathogen into the brain [25].
The VHH, the core part of the sdAb, are unique in 
terms of size, epitope recognition, resistance to the heat 
and harsh pH, and show ability to penetrate into diffi-
cult areas or get through barriers (like blood brain bar-
rier) [3, 17, 29, 30]. Existing pipelines for production of 
the sdAbs rely on the active immunization of animals, 



















Fig. 9 Quantitative phage ELISA. Bar graph depicts interaction of selected phage clones to H‑OspA (dark‑grey), non‑related antigen SAA (light‑grey), 
and to the wells without any antigen (white bars). PhC1‑19—individual phage clones. Binding affinities of PhC5, PhC9, and PhC19 phage clones 
to H‑OspA were significantly lower (P > 0.05) than other clones indicated with asterisk. Two phages, PhC10 and PhC19, showed weak non‑specific 
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m/z m/z a b c d 
Fig. 10 Soluble sdAbs. Presence and purity of soluble sdAbs were assessed by SDS‑PAGE (a, b lanes). Molecular weights measured by MALDI–TOF 
(spectra c, d) of the purified sdAbs corresponded with theoretical molecular weights predicted in silico (PhC11—14.98 kDa, PhC12—14.34 kDa, pre‑
dicted with Geneious Pro software). x‑axis in MALDI spectra depicts m/z ratio while y‑axis depicts intensity [a.u.]. Values 14,982.545 and 14,348.150 
are in daltons
Table 2 Kinetic analysis of selected VHH clones
VHH KD Ka (1/Ms) Kd (1/s)
PhC11 4.291E−6 1.366E4 5.861E−2
PhC12 7.905E−4 1.854E2 1.465E−1
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approach is feasible in case of small animals (like rabbits, 
rats etc.), but cumbersome and costly in case of camel-
ids. Another downside of active immunization is that it 
becomes extremely complicated when antigens are of 
high pathogenicity (infectious agents), toxicity or repre-
sents nonimmunogenic small molecules [31, 32]. Num-
ber of mRNA copies encoding antigen specific VHH are 
obviously higher in B cell repertoire of actively immu-
nized animal than in naïve individual. This fact increases 
chances of getting more antigen specific nanobodies with 
stronger affinity. Several authors have attempted isolation 
of sdAbs from naïve libraries [33, 34], however struggled 
with lower antigen binding affinity or specificity. More-
over, they required extremely large sdAb libraries (e.g. 
2.5–5 ×  107 and more). To overcome several disadvan-
tages of active immunization or naïve libraries, we set to 
establish a pipeline for in  vitro immunization followed 
by selection of antigen specific sdAb from sdAb-phage 
library.
Antigen-induced in vitro production of antibodies was 
attempted previously, however human PBMCs were used 
in their experiments and minimum of 8 days of lympho-
cyte culture was needed to obtain antibodies [22, 26]. 
Hitherto, there is no report that presents in vitro immu-
nization of PBMCs from camelid animals. Two crucial 
components are required for successful in vitro immuni-
zation, the LLME (also called as Leu–Leu–OMe) and ILs. 
PBMCs contain lysosome-rich cytolytic T cell subpopula-
tion, which is necessary to be removed from culture [35]. 
This subpopulation, sensitive to LLME, was thus treated 
before in vitro immunization in our study. Species-spec-
ificity of ILs, the second crucial component in in  vitro 
immunization is important to address here. Species speci-
ficity of ILs was tested previously [36]. Authors found that 
human IL-2 efficiently stimulated proliferation of mouse 
T cells, however efficiency of mouse IL-2 to stimulated 
human T cells was 170-fold lower. It is noteworthy that, 
IL-4 (B cell stimulatory factor 1) is highly species specific. 
No B cell stimulatory activity was observed when mouse 
IL-4 was used to stimulate human lymphocytes and vice a 
versa [36]. Owing to this fact, we decided to produce IL-2 
and IL-4 specific for the given camelid species. The ability 
to stimulate lymphocyte proliferation by recombinant ILs 
produced in our study was evident (Fig. 4).
Despite enormous advantages over other methods of 
antibody production, in  vitro immunization may suffer 
from some inconveniences such as the IgM/IgG ratio, 
because this method tends to favor IgM isotypes. In the 
present study B cells were exposed to H-OspA only long 
enough to recognize the antigen and induce synthesis 
of mRNA copies that encode antigen-specific sdAbs. 
Shortening of the lymphocyte culturing to 4  day (as 
used in the present work) does not give sufficient time 
to differentiate B lymphocytes into plasma cells, which 
are primarily associated with production of IgM isotypes 
antibodies [22].
Antibody phage display based on phagemid vector 
has been successfully developed and used in the recent 
years. Several modifications in phagemid backbone were 
made to simplify cloning and library construction [37–
42]. pSex81 phagemid used in our study was specifically 
developed for cloning of immunoglobulin heavy and light 
chain gene fragments isolated from human or mouse 
[43]. It was then modified for expression of functional 
single-chain Fv antibody—pIII fusion proteins on the 
surface of M13 bacteriophages [44]. pSex81 was also used 
successfully for construction of naïve sdAb library [45] 
production of complete human IgG [46], and for directed 
protein evolution [47]. Transformation efficiency of 
pSex81 is declared ~1 × 108 CFU/μg DNA with chemi-
cally competent E. coli (XL1-Blue). The efficiency we 
obtained was ~1 × 109 CFU/μg DNA. High cloning and 
transformation efficiency is crucial aspect in sdAb library 
construction as it directly affects the size and diversity 
of library, and moreover, increases the chances of get-
ting antigen specific antibody with high affinity. Size of 
the library obtained in the present study was 1.3 × 106, 
which is within the required range suitable for captur-
ing antigen specific sdAb from immunized library. The 
use of NcoI restriction site incorporated in pSex81 may 
obstruct subcloning. Random presence of NcoI in the 
CDRs results in production of fragmented VHH and thus 
increases redundancy of clones. Few of the transfectants 
sequenced in our study showed such fragmentation (e.g. 
absence of framework-1 or framework-4, results not pre-
sented). Choice of alternative rare restriction site like SfiI 
can easily overcome this drawback. As far as the diversity 
of library is concerned, sequence distance matrix plotted 
on VHH sequences obtained from our library and refer-
ence camelid VHH gene (KF013132) indicated complete 
non-specificity (i.e. high divergence, Fig. 6) of the library.
The affinities of soluble sdAbs produced from PhC11 
and PhC12 were in micromolar range. To increase the 
affinity, soluble antibodies can be produced in periplas-
mic space of E. coli [48, 49] to allow formation of disulfide 
bonds and higher stability, or in eukaryotic secretory 
expression system like Leishmania tarentolae to main-
tain the post-translational modifications. Another option 
of improving the affinity may be the mutational hotspot 
randomization [50] or forming dimers by making fusion 
with alkaline phosphatase [51].
Conclusions
In summary, joining the in  vitro immunization of 
camelid lymphocytes and the phage display offers many 
advantages. In  vitro immunization enables the efficient 
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expansion of antigen-specific B cells among the PBMCs 
from only 10  ml of blood that substantially reduces the 
cost required to maintain a camelid herd. It also avoids 
time-consuming and laborious work involved in the con-
struction of an extremely diverse synthetic or naïve librar-
ies to obtain antigen-specific sdAb. Moreover, various 
immunogens including infectious agents and cell surface 
antigens can be employed easily in in vitro conditions to 
sensitize PBMCs. The pipeline presented here can be used 
to enrich antigen-specific B cells in camelid PBMCs and 
obtain antigen-specific sdAbs in short period.
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